Meta-analysis: The efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease

Journal of Neural Transmission

Volumn 114, Issue 5, 2007, Pages 629-634

  Wei, Z H ^a   He, Q B ^a   Wang, H ^a   Su, B H ^a   Chen, H Z ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Cerebrolysin; Clinical trials; Dementia; Meta analysis; Neurotrophic therapy

Indexed keywords

CEREBROLYSIN; NOOTROPIC AGENT; PLACEBO;

ALZHEIMER DISEASE; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITION; DAILY LIFE ACTIVITY; DATA ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZATION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ALZHEIMER DISEASE; AMINO ACIDS; BRAIN; COGNITION DISORDERS; DRUG ADMINISTRATION SCHEDULE; HUMANS; NOOTROPIC AGENTS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 34247492801     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-007-0630-y     Document Type: Article

References (17)

1. XA Alvarez R Cacabelos M Laredo V Couceiro C Sampedro M Varela L Corzo L Fernandez-Novoa M Vargas M Aleixandre C Linares E Granizo D Muresanu H Moessler 2006 A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease Eur J Neurol 13 43 54
2. CY Bae CY Cho K Cho BH Oh KG Choi HS Lee SP Jung 2000 A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease J Am Geriatr Soc 48 1566 1571
3. RJ Boado 2001 Amplification of blood-brain barrier GLUT1 glucose transporter gene expression by brain-derived peptides Neurosci Res 40 337 342
4. P Eder I Reinprecht E Schreiner G Skofitsch M Windisch 2001 Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: an immunohistochemical study on aged rats Histochem J 33 605 612
5. KM Frick DL Price VE Koliatsos AL Markowska 1997 The effects of nerve growth factor on spatial recent memory in aged rats persist after discontinuation of treatment J Neurosci 17 2543 2550
6. DF Muresanu M Rainer H Moessler 2002 Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin J Neural Transm Suppl 62 277 285
7. SLT Normand 1999 Meta-analysis: formulating, evaluating, combining, and reporting Stat Med 18 321 359
8. M Panisset S Gauthier H Moessler M Windisch Cerebrolysin Study Group 2002 Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent J Neural Transm 109 1089 1104
9. E Rockenstein A Adame M Mante G Larrea L Crews M Windisch H Moessler E Masliah 2005 Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin J Neural Transm 112 269 282
10. E Rockenstein M Torrance M Mante A Adame A Paulino JB Rose L Crews H Moessler E Masliah 2006 Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease J Neurosci Res 15 1252 1261
11. E Ruether R Rither M Apecechea S Freytag M Windisch 1994 Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT) Pharmacopsychiatry 27 32 40
12. E Ruether R Ritter M Apecechea S Freytag R Gmeinbauer M Windisch 2000 Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy J Neural Transm 107 815 829
13. E Ruether R Husmann E Kinzler E Diabl D Klingler J Spatt R Ritter R Schmidt Z Taneri W Winterer D Koper S Kasper M Rainer H Moessler 2001 A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patient with mild to moderate Alzheimer's disease Int Clin Psychopharmacol 16 253 263
14. E Ruether XA Alvarez M Rainer H Moessler 2002 Sustained improvement of cognition and global function in patients with moderately severe AD: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin J Neural Transm Suppl 62 265 275
15. A Seiger A Nordberg H von Holst L Backman T Ebendal I Alafuzoff K Amberla P Hartvig A Herlitz A Lilja 1993 Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy Behav Brain Res 57 255 261
16. A Whitehead 2002 Meta-analysis of controlled clinical trial J Wiley Chichester
17. Sf Xiao H Yan P Yao 2000 Efficacy of FPF1070 (Cerebrolysin) in patients with Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled trial Clin Drug Invest 19 43 53